Shiga toxin-induced complement-mediated hemolysis and release of complement-coated red blood cell-derived microvesicles in hemolytic uremic syndrome

Journal of Immunology

Volumn 194, Issue 5, 2015, Pages 2309-2318

  Arvidsson, Ida ^a   Ståhl, Anne Lie ^a   Hedström, Minola Manea ^a   Kristoffersson, Ann Charlotte ^a   Rylander, Christian ^b   Westman, Julia S ^c   Storry, Jill R ^c   Olsson, Martin L ^c   Karpman, Diana ^a,c  

^a LUND UNIVERSITY   (Sweden)

^b SAHLGRENSKA UNIVERSITY HOSPITAL   (Sweden)

^c LUND UNIVERSITY   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

COMPLEMENT COMPONENT C3; COMPLEMENT COMPONENT C9; ECULIZUMAB; EDETIC ACID; LACTATE DEHYDROGENASE; SHIGA TOXIN; SURAMIN; CERAMIDE TRIHEXOSIDE; COMPLEMENT MEMBRANE ATTACK COMPLEX; GLOBOTRIAOSYLCERAMIDE; MONOCLONAL ANTIBODY; PURINERGIC P2 RECEPTOR; PURINERGIC P2 RECEPTOR ANTAGONIST;

ADULT; AGED; CENTRIFUGATION; CHILD; CLINICAL ARTICLE; CLINICAL FEATURE; CONFERENCE PAPER; CONTROLLED STUDY; CYTOKINE RELEASE; ENZYME ACTIVITY; ERYTHROCYTE; FEMALE; FLOW CYTOMETRY; GENOTYPE; HEMOLYSIS; HEMOLYTIC UREMIC SYNDROME; HUMAN; MALE; PHENOTYPE; PRESCHOOL CHILD; PRIORITY JOURNAL; PROTEIN BINDING; SCHOOL CHILD; SHIGA TOXIN PRODUCING ESCHERICHIA COLI; SIGNAL TRANSDUCTION; BLOOD; CHEMISTRY; COATED VESICLE; COMPLEMENT ACTIVATION; DRUG EFFECTS; ESCHERICHIA COLI INFECTION; ESCHERICHIA COLI O157; GENE EXPRESSION; GENETICS; IMMUNOLOGY; INFANT; METABOLISM; MICROBIOLOGY; MIDDLE AGED; PATHOGENICITY; PATHOLOGY; SECRETION (PROCESS);

ADULT; AGED; ANTIBODIES, MONOCLONAL, HUMANIZED; CHILD; CHILD, PRESCHOOL; COATED VESICLES; COMPLEMENT ACTIVATION; COMPLEMENT C3; COMPLEMENT C9; COMPLEMENT MEMBRANE ATTACK COMPLEX; EDETIC ACID; ERYTHROCYTES; ESCHERICHIA COLI INFECTIONS; ESCHERICHIA COLI O157; FEMALE; GENE EXPRESSION; HEMOLYSIS; HEMOLYTIC-UREMIC SYNDROME; HUMANS; INFANT; L-LACTATE DEHYDROGENASE; MALE; MIDDLE AGED; PURINERGIC P2 RECEPTOR ANTAGONISTS; RECEPTORS, PURINERGIC P2; SHIGA TOXIN; SURAMIN; TRIHEXOSYLCERAMIDES;

EID: 84924358744     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.1402470     Document Type: Conference Paper

References (43)

1. Besbas, N., D. Karpman, D. Landau, C. Loirat, W. Proesmans, G. Remuzzi, G. Rizzoni, C. M. Taylor, N. Van de Kar, and L. B. Zimmerhackl, European Paediatric Research Group for HUS. 2006. A classification of hemolytic uremic syndrome and thrombotic thrombocytopenic purpura and related disorders. Kidney Int. 70: 423-431.
2. Tarr, P. I., C. A. Gordon, and W. L. Chandler. 2005. Shiga-toxin-producing Escherichia coli and haemolytic uraemic syndrome. Lancet 365: 1073-1086.
3. Bielaszewska, M., A. Mellmann, W. Zhang, R. Köck, A. Fruth, A. Bauwens, G. Peters, and H. Karch. 2011. Characterisation of the Escherichia coli strain associated with an outbreak of haemolytic uraemic syndrome in Germany, 2011: a microbiological study. Lancet Infect. Dis. 11: 671-676.
4. Ruggenenti, P., M. Noris, and G. Remuzzi. 2001. Thrombotic microangiopathy, hemolytic uremic syndrome, and thrombotic thrombocytopenic purpura. Kidney Int. 60: 831-846.
5. Túri, S., I. Németh, I. Vargha, and B. Matkovics. 1994. Oxidative damage of red blood cells in haemolytic uraemic syndrome. Pediatr. Nephrol. 8: 26-29.
6. Lindberg, A. A., J. E. Brown, N. Strömberg, M. Westling-Ryd, J. E. Schultz, and K. A. Karlsson. 1987. Identification of the carbohydrate receptor for Shiga toxin produced by Shigella dysenteriae type 1. J. Biol. Chem. 262: 1779-1785.
7. Bitzan, M., S. Richardson, C. Huang, B. Boyd, M. Petric, and M. A. Karmali. 1994. Evidence that verotoxins (Shiga-like toxins) from Escherichia coli bind to P blood group antigens of human erythrocytes in vitro. Infect. Immun. 62: 3337-3347.
8. Spitalnik, P. F., and S. L. Spitalnik. 1995. The P blood group system: biochemical, serological, and clinical aspects. Transfus. Med. Rev. 9: 110-122.
9. Monnens, L., J. Molenaar, P. H. Lambert, W. Proesmans, and P. van Munster. 1980. The complement system in hemolytic-uremic syndrome in childhood. Clin. Nephrol. 13: 168-171.
10. Robson, W. L., A. K. Leung, G. H. Fick, and A. I. McKenna. 1992. Hypocomplementemia and leukocytosis in diarrhea-associated hemolytic uremic syndrome. Nephron 62: 296-299.
11. Ståhl, A. L., L. Sartz, and D. Karpman. 2011. Complement activation on platelet-leukocyte complexes and microparticles in enterohemorrhagic Escherichia coli-induced hemolytic uremic syndrome. Blood 117: 5503-5513.
12. Thurman, J. M., R. Marians, W. Emlen, S. Wood, C. Smith, H. Akana, V. M. Holers, M. Lesser, M. Kline, C. Hoffman, et al. 2009. Alternative pathway of complement in children with diarrhea-associated hemolytic uremic syndrome. Clin. J. Am. Soc. Nephrol. 4: 1920-1924.
13. Ham, T. H., and J. H. Dingle. 1939. Studies on destruction of red blood cells. Ii. Chronic hemolytic anemia with paroxysmal nocturnal hemoglobinuria: Certain immunological aspects of the hemolytic mechanism with special reference to serum complement. J. Clin. Invest. 18: 657-672.
14. Strübing, P. 1882. Paroxysmale Hämoglobinurie. Dtsch. Med. Wochenschr. 8: 17-21.
15. Yazdanbakhsh, K. 2005. Controlling the complement system for prevention of red cell destruction. Curr. Opin. Hematol. 12: 117-122.
16. Hejl, J. L., M. Skals, J. Leipziger, and H. A. Praetorius. 2013. P2X receptor stimulation amplifies complement-induced haemolysis. Pflugers Arch. 465: 529-541.
17. Skals, M., N. R. Jorgensen, J. Leipziger, and H. A. Praetorius. 2009. Alpha-hemolysin from Escherichia coli uses endogenous amplification through P2X receptor activation to induce hemolysis. Proc. Natl. Acad. Sci. USA 106: 4030-4035.
18. Wang, L., G. Olivecrona, M. Götberg, M. L. Olsson, M. S. Winzell, and D. Erlinge. 2005. ADP acting on P2Y13 receptors is a negative feedback pathway for ATP release from human red blood cells. Circ. Res. 96: 189-196.
19. Samuelsson, O., P. Follin, M. Rundgren, C. Rylander, D. Selga, and A. Ståhl. 2012. [The HUS epidemic in the summer of 2011 was severe. German and Swedish experiences of the EHEC outbreak]. Läkartidningen 109: 1230-1234.
20. Svenungsson, B., A. Lagergren, E. Ekwall, B. Evengard, K. O. Hedlund, A. Kärnell, S. Löfdahl, L. Svensson, and A. Weintraub. 2000. Enteropathogens in adult patients with diarrhea and healthy control subjects: a 1-year prospective study in a Swedish clinic for infectious diseases. Clin. Infect. Dis. 30: 770-778.
21. Thuresson, B., J. S. Westman, and M. L. Olsson. 2011. Identification of a novel A4GALT exon reveals the genetic basis of the P1/P2 histo-blood groups. Blood 117: 678-687.
22. 2+ exchanger in guinea pig airway smooth muscle. Eur. J. Pharmacol. 674: 439-444.
23. Morigi, M., M. Galbusera, S. Gastoldi, M. Locatelli, S. Buelli, A. Pezzotta, C. Pagani, M. Noris, M. Gobbi, M. Stravalaci, et al. 2011. Alternative pathway activation of complement by Shiga toxin promotes exuberant C3a formation that triggers microvascular thrombosis. J. Immunol. 187: 172-180.
24. Dhaliwal, G., P. A. Cornett, and L. M. Tierney, Jr. 2004. Hemolytic anemia. Am. Fam. Physician 69: 2599-2606.
25. Tissot, J. D., O. Rubin, and G. Canellini. 2010. Analysis and clinical relevance of microparticles from red blood cells. Curr. Opin. Hematol. 17: 571-577.
26. Ståhl, A. L., L. Sartz, A. Nelsson, Z. D. Békássy, and D. Karpman. 2009. Shiga toxin and lipopolysaccharide induce platelet-leukocyte aggregates and tissue factor release, a thrombotic mechanism in hemolytic uremic syndrome. PLoS ONE 4: e6990.
27. Rubin, O., D. Crettaz, J. D. Tissot, and N. Lion. 2010. Microparticles in stored red blood cells: submicron clotting bombs? Blood Transfus. 8(Suppl. 3): s31-s38.
28. Rubin, O., D. Crettaz, J. D. Tissot, and N. Lion. 2010. Pre-analytical and methodological challenges in red blood cell microparticle proteomics. Talanta 82: 1-8.
29. Majumder, R., M. A. Quinn-Allen, W. H. Kane, and B. R. Lentz. 2008. A phosphatidylserine binding site in factor Va C1 domain regulates both assembly and activity of the prothrombinase complex. Blood 112: 2795-2802.
30. Wu, J. R., C. Zhou, R. Majumder, D. D. Powers, G. Weinreb, and B. R. Lentz. 2002. Role of procoagulant lipids in human prothrombin activation. 1. Prothrombin activation by factor X(a) in the absence of factor V(a) and in the absence and presence of membranes. Biochemistry 41: 935-949.
31. Zipfel, P. F., and C. Skerka. 2009. Complement regulators and inhibitory proteins. Nat. Rev. Immunol. 9: 729-740.
32. Fong, J. S., and R. A. Good. 1972. Suramin - a potent reversible and competitive inhibitor of complement systems. Clin. Exp. Immunol. 10: 127-138.
33. Munksgaard, P. S., T. Vorup-Jensen, J. Reinholdt, C. M. Söderström, K. Poulsen, J. Leipziger, H. A. Praetorius, and M. Skals. 2012. Leukotoxin from Aggregatibacter actinomycetemcomitans causes shrinkage and P2X receptor-dependent lysis of human erythrocytes. Cell. Microbiol. 14: 1904-1920.
34. Skals, M., U. B. Jensen, J. Ousingsawat, K. Kunzelmann, J. Leipziger, and H. A. Praetorius. 2010. Escherichia coli alpha-hemolysin triggers shrinkage of erythrocytes via K(Ca)3.1 and TMEM16A channels with subsequent phosphatidylserine exposure. J. Biol. Chem. 285: 15557-15565.
35. Skals, M., J. Leipziger, and H. A. Praetorius. 2011. Haemolysis induced by α-toxin from Staphylococcus aureus requires P2X receptor activation. Pflugers Arch. 462: 669-679.
36. Pizzirani, C., D. Ferrari, P. Chiozzi, E. Adinolfi, D. Sandonà, E. Savaglio, and F. Di Virgilio. 2007. Stimulation of P2 receptors causes release of IL-1beta-loaded microvesicles from human dendritic cells. Blood 109: 3856-3864.
37. Turola, E., R. Furlan, F. Bianco, M. Matteoli, and C. Verderio. 2012. Microglial microvesicle secretion and intercellular signaling. Front Physiol 3: 149.
38. Wilson, H. L., S. E. Francis, S. K. Dower, and D. C. Crossman. 2004. Secretion of intracellular IL-1 receptor antagonist (type 1) is dependent on P2X7 receptor activation. J. Immunol. 173: 1202-1208.
39. Brigotti, M., P. L. Tazzari, E. Ravanelli, D. Carnicelli, L. Rocchi, V. Arfilli, G. Scavia, F. Minelli, F. Ricci, P. Pagliaro, et al. 2011. Clinical relevance of Shiga toxin concentrations in the blood of patients with hemolytic uremic syndrome. Pediatr. Infect. Dis. J. 30: 486-490.
40. Brigotti, M., A. Caprioli, A. E. Tozzi, P. L. Tazzari, F. Ricci, R. Conte, D. Carnicelli, M. A. Procaccino, F. Minelli, A. V. Ferretti, et al. 2006. Shiga toxins present in the gut and in the polymorphonuclear leukocytes circulating in the blood of children with hemolytic-uremic syndrome. J. Clin. Microbiol. 44: 313-317.
41. te Loo, D. M., L. A. Monnens, T. J. van Der Velden, M. A. Vermeer, F. Preyers, P. N. Demacker, L. P. van Den Heuvel, and V. W. van Hinsbergh. 2000. Binding and transfer of verocytotoxin by polymorphonuclear leukocytes in hemolytic uremic syndrome. Blood 95: 3396-3402.
42. Menne, J., M. Nitschke, R. Stingele, M. Abu-Tair, J. Beneke, J. Bramstedt, J. P. Bremer, R. Brunkhorst, V. Busch, R. Dengler, et al; EHEC-HUS consortium. 2012. Validation of treatment strategies for enterohaemorrhagic Escherichia coli O104:H4 induced haemolytic uraemic syndrome: case-control study. BMJ 345: e4565.
43. Karpman, D. 2012. Management of Shiga toxin-associated Escherichia coli-induced haemolytic uraemic syndrome: randomized clinical trials are needed. Nephrol. Dial. Transplant. 27: 3669-3674.